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Abstract
Background Subacute cutaneous lupus erythematosus (S(CLE) lacks consensus diagnostic criteria and the pathogenesis is 
poorly understood. There are increasing reports of SCLE induced by monoclonal antibodies (mAbs), but there are limited 
data on the aetiology, clinical characteristics and natural course of this disease.
Methods We devised a set of diagnostic criteria for SCLE in collaboration with a multinational, multispecialty panel. This 
systematic review employed a two-layered search strategy of five databases for cases of mAb-induced SCLE (PROSPERO 
registered protocol CRD42019116521). To explore the relationship between relative mAb use and the number of SCLE 
cases reported, the estimated number of mAb users was modelled from 2013 to 2018 global commercial data and estimated 
annual therapy costs.
Results From 40 papers, we identified 52 cases of mAb-induced SCLE, occurring in a cohort that was 73% female and with 
a median age of 61 years. Fifty percent of cases were induced by anti-tumour necrosis factor (TNF)-ɑ agents. A median 
of three drug doses preceded SCLE onset and the lesions lasted a median of 7 weeks after drug cessation. Oral and topi-
cal corticosteroids were most frequently used. Of the licensed mAbs, adalimumab, denosumab, rituximab, etanercept and 
infliximab were calculated to have the highest relative number of yearly users based on global sales data. Comparing the 
number of mAb-induced SCLE cases with estimated yearly users, the checkpoint inhibitors pembrolizumab and nivolumab 
showed strikingly high rates of SCLE relative to their global use, but ipilimumab did not.
Conclusion We present the first systematic review characterising mAb-induced SCLE with respect to triggers, clinical signs, 
laboratory findings, prognosis and treatment approaches. We identify elevated rates associated with the use of checkpoint 
inhibitors and anti-TNFɑ agents.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 8-020-00320 -5) contains 
supplementary material, which is available to authorized users.
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1 Introduction
In an era of genomic medicine, the clear distinction of dis-
ease phenotypes is as critical as ever [1]. Integrated network 
analyses of—omics signatures are driving molecular dis-
ease classification that transcends organ-specific phenotypes 
[2]. However, a reductionist approach to disease classifica-
tion retains its utility in the clinical setting and facilitates 
research [3]. Precise clinical phenotyping and confident 
diagnoses guide the initial therapeutic approach, provide an 
access key for interrogating large-scale datasets and make 
Key Points 
Monoclonal antibody (mAb)-induced subacute cutane-
ous lupus erythematosus (SCLE) has been reported in 52 
patients across a range of 17 mAbs.
Adalimumab, denosumab and rituximab were estimated 
to have the greatest number of annual users.
Checkpoint inhibitors and anti-tumour necrosis factor-ɑ 
agents are associated with high rates of SCLE relative to 
the estimated global yearly use and other mAbs.
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2.1  Eligibility Criteria
A lack of formalised consensus for the classification criteria 
of SCLE [11–13] required the development of inclusion cri-
teria by a multinational panel of dermatologists, rheumatolo-
gists and a dermatohistopathologist (Table 1). The agreed 
criteria incorporated morphological features specified by the 
European Society of Cutaneous Lupus Erythematosus (EUS-
CLE) [18] and previously published features of the disease 
[14, 19, 20]. To avoid ambiguity, the presence of lesions in 
sun-exposed regions was used to define ‘photosensitivity’. A 
conservative boundary of 2 years post-initiation of therapy 
was used for inclusion as a drug-induced case [21]. Reports 
lacking sufficient detail to confirm inclusion criteria from 
three or more categories were excluded.
2.2  Data Sources and Search Strategy
Five databases were searched without any time limitations, 
with final searches conducted on 22 August 2019 (Fig. 1). 
The search strategy was designed in two layers using terms 
that included ‘cutaneous’, ‘subacute’, ‘skin’ and ‘lupus’ 
and terms for mAb therapies, including ‘monoclonal anti-
body’ and 256 named biologics (electronic supplementary 
Fig. S1). Alternative spellings, abbreviations and synonyms 
were included. Additional studies were identified from the 
review of abstracts from all ‘Skin Immune-Mediated Inflam-
matory Disease’ international conferences [22], manual 
searching of included study references, and correspondence 
with authors to identify missing data and obtain further 
patients from case series.
2.3  Data Collection and Analysis
Following duplicate removal, screening of abstracts, and 
critical appraisal, data extraction was performed by two 
reviewers independently using the same Microsoft Excel 
template (Microsoft Corporation, Redmond, WA, USA). 
Studies were eligible if they described human patients of 
any age and included individual-level primary data where 
sufficient patient characteristics could be extracted (elec-
tronic supplementary Table S1). English and non-English-
language papers were included, with translation supplied 
by Google Translate for the initial screening. Variables 
extracted are specified in electronic supplementary Appen-
dix S1. Verification of data extraction for German and Span-
ish papers was undertaken by bilingual doctors who were 
native speakers or had medical language qualifications in 
the language. Abstract screening disparities were resolved 
by a third reviewer, while appraisal and extraction disparities 
were resolved by discussion.
data computationally accessible for machine learning analy-
ses [4, 5]. The phenotypic heterogeneity and overlap of auto-
immune diseases provide a particular challenge with regard 
to clearly defining diagnostic criteria [6].
Lupus erythematosus (LE) exemplifies this classifica-
tion challenge, in comprising a spectrum of autoimmune 
pathology, where aberrant inflammatory processes lead 
to cell injury with diverse patterns of disease. Cutaneous 
lesions may arise in isolation or as a feature of systemic 
lupus erythematosus (SLE), with a prevalence of around 70 
in 100,000 [7]. In conventional classification, these cuta-
neous manifestations are classified as acute, subacute or 
chronic subtypes according to rash morphology, laboratory 
criteria and associated characteristics [8]. Such distinctions 
assist prognostication and predictions of whether patients are 
likely to manifest systemic features of LE [9].
Subacute cutaneous lupus erythematosus (SCLE) is a 
phenotypic subset of CLE, first described in 1979 as an 
intermediary between transient, acute CLE, and chronic, 
scarring CLE [10]. Forty years on, a consensus on the diag-
nostic criteria of SCLE remains elusive [11–13]. This lack 
of phenotypic clarity is exemplified in the pragmatic search 
methodology of previous reviews, where a published diag-
nosis of SCLE has been sufficient for inclusion rather than 
specified, standardised clinical criteria [14, 15]. With these 
considerations in mind, we aimed to clinically characterise 
and formalise the phenotype of SCLE to facilitate systematic 
review.
Numerous medications have been implicated in triggering 
the development of SCLE [14, 16], including monoclonal 
antibody (mAb) products [14, 17] (hereafter referred to as 
‘mAb-induced SCLE’ for simplicity). The clinical char-
acterisation of mAb-induced SCLE has not been explored 
in systematic review of multiple databases. In particular, 
because of the specificity of mAbs and their immunomodu-
latory effects, patients with antibody-induced SCLE provide 
a unique perspective of the condition. Therefore, the aim of 
this review was to define and clinically characterise SCLE 
induced by mAbs, to provide a clearer phenotype and prog-
nosis. We then explored the relationship between relative 
mAb use on a global scale and the number of SCLE cases 
reported.
2  Methods
This review was conducted according to the PROSPERO 
registered protocol (CRD42019116521, accessible at https 
://www.crd.york.ac.uk/prosp ero/displ ay_recor d.php?Recor 
dID=11652 1) and the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) guidelines.
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Table 1  Inclusion and exclusion 
criteria used for monoclonal 
antibody-induced SCLE
SCLE subacute cutaneous lupus erythematosus, ANA antinuclear antibody, ENA extractable nuclear anti-





 Papulosquamous, plaques or papules with scale or desquamation, psoriasiform
 ‘SCLE’ without exclusion terms
Possible:
 Plaques or papules
 Erythema with scale or desquamation
Serology ANA-positive, anti-Ro antibody-positive OR ENA-positive
Photosensitivity Lesions in sun-exposed areas:
Face, neck OR arms
Histology Prespecified:
–IF dermatitis
–Study synonyms: IF change, IF reaction, IF infiltrate, lichenoid reaction
–‘Consistent with SCLE/lupus’
 Supportive details included in cases:
–Lymphocytic infiltrate of perivascular/dermoepidermal regions/junction/peri-
follicular/superficial/deep/dermis/epidermis
–Parakeratosis, orthokeratosis, dyskeratosis, hyperkeratosis, necrotic/apoptotic 
keratinocytes
–Mucin in dermis, colloid bodies, colloidal iron staining
Exclusion
Morphology Nonspecific/contradictory CLE terms in the absence of inclusion terms
Chronic, discoid, tumidus, panniculitis, profundus, chilblain, atrophic, scarring
Acute, malar, macular, butterfly
Stevens–Johnson syndrome
Palpable purpura, nodules, bullous
Fig. 1  Study profile of the systematic review for monoclonal antibody-induced subacute cutaneous lupus erythematosus
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Risk of bias was considered to be inherently low given the 
observational nature of case reports. The publication quality 
was appraised according to the accuracy of descriptions and 
figures, the consistency of values, and appropriate application 
of statistical tests (electronic supplementary Appendix S1).
2.4  Monoclonal Antibody (mAb) Use
To determine whether large-scale use of anti-tumour necro-
sis factor (TNF)-ɑ agents accounted for high rates of SCLE, 
the relative global use of mAb products was estimated by 
modelling yearly global sales data (2013–2018) and dividing 
by the mean annual therapy cost taken from a truncated nor-
mal distribution of costs across different settings and indica-
tions. The 20 mAb products with the highest global sales in 
2013 (licenced in the US and Europe as of November 2013 
[23]) were reviewed. These were updated to include the top 
10 mAbs with the highest sales in 2018 [24], amounting to 
22 drugs. Biosimilars and profits from distributing compa-
nies for the US and the rest of the world were included in the 
total global sales from 2013 to 2018 (inclusive, values from 
2018 shown in Table 3). Global sales were cross-checked 
with manufacturer financial reviews, additional studies and 
news reports [24, 25], and were assumed to follow a normal 
distribution, with fluctuations in global sales captured in the 
simulation model based on historical data from 2013.
A truncated normal distribution was used to estimate the 
average annual therapy costs with the upper bound based 
on US data, as the US is reported as having exception-
ally high biologic costs [26]. 2017 and 2015 US published 
acquisition costs were extracted to derive the upper bound 
of annual treatment costs [27, 28] (electronic supplementary 
Table S2). For some mAb therapies, vastly disparate therapy 
costs were associated with differing indications [27]; there-
fore, a weighted average of costs was calculated according 
to the cost of each treatment regimen and the proportion 
of sales attributable to each indication (where provided 
by pharmaceutical companies [electronic supplementary 
Appendix S1 and Table S4]). The lower bound of annual 
treatment costs was based on the UK annual therapy costs 
using the UK National Institute for Health and Care Excel-
lence (NICE) guidance on dosing and treatment costs [29] 
(electronic supplementary Table S3).
For the lower bound UK values, average costs were esti-
mated for the treatment received by a single patient over 
1 year, for adult indications, including induction and mainte-
nance regimens. Yearly therapy prices were calculated for a 
range of oncological, musculoskeletal, respiratory and rheu-
matological indications of each drug as shown (electronic 
supplementary Table S3). Doses were calculated for a 70 kg 
adult with a body surface area of 1.75 m2. For drug treat-
ments requiring a course duration of < 1 year, the average 
duration of treatment was taken from NICE guidance where 
provided, or the median course of treatment from available 
clinical trials (electronic supplementary Table S3). UK treat-
ment costs were derived from September 2015 vial prices 
(British National Formulary 70th edition), unless stated. UK 
costs in 2013–2018 Great British Pounds (GBP) were con-
verted to 2018 US$ using implied standard conversion rates 
based on purchasing power parities from the International 
Monetary Fund.
2.5  Data Handling
Descriptive statistics are provided according to information 
available in reports without adjustment. Regarding miss-
ing data, confidence intervals in Fig. 2 reflect proportions 
assuming missing data parameters were all positive or neg-
ative results. Statistical analysis using two-tailed Fisher’s 
exact test was used where appropriate.
3  Results
3.1  Case Inclusion
Overall, 1788 unique abstracts from database searches and 
conference abstracts were screened for inclusion (Fig. 1). 
Reasons for exclusion were inability to extract patient data 
from aggregated cohorts, lesions occurring more than 
2 years after mAb onset, an alternative diagnosis implied by 
rash description (Table 1), or reviews/expert opinion lack-
ing clinical data. After manual searches, 103 full texts were 
critically appraised, with the inclusion of 40 studies. Reports 
of 52 individual patients had sufficient detail for inclusion 
(electronic supplementary Table S1), with inclusion criteria 
from at least three domains as described in Table 1; 69% had 
a stated diagnosis of SCLE by the original paper authors.
3.2  Patient Characteristics
The median age of onset for mAb-induced SCLE was 
61 years (interquartile range [IQR] 51–66) and 73% of 
patients were female (38/52). The majority of patients had 
White European ancestry (94%, 27/33). Inflammatory arthri-
tis was the most common indication for mAb therapy at the 
time of the SCLE eruption (40%, 20/50). The next most 
common indications for therapy leading to SCLE included 
advanced melanoma (12%, 6/50), psoriasis/psoriatic arthritis 
(10%, 5/50) and metastatic lung cancer (8%, 4/50).
3.3  Drug Characteristics
mAbs implicated in inducing SCLE are shown in Table 2. 
The median time to onset after initiating mAb therapy was 
9 weeks (IQR 3–17) [Table 2]. Given the weekly or monthly 
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regimens often used for biologic therapy, the median num-
ber of doses prior to onset was 3 (IQR 2–6) and the modal 
number of doses was 2. Etanercept was most frequently 
associated with mAb-induced SCLE (19%, 10/52). mAbs 
interacting with the TNFɑ pathway were most often impli-
cated in the development of the disease, with 50% of cases 
involving either etanercept, golimumab, infliximab or adali-
mumab (26/52). Checkpoint inhibitors were the second most 
frequent type of mAb causing induced SCLE (25%, 13/52). 
Among anti-vascular endothelial growth factor (VEGF) 
agents, aflibercept was not associated with drug reactions 
of SCLE, whereas cases were reported for bevacizumab and 
ranibizumab.
Lesions were most frequently distributed over the trunk 
and arms (68% and 64%, 30/44 and 28/44, respectively) 
[Fig. 2]. Eight-five percent of patients were ANA-positive 
(39/46), 62% had anti-Ro antibodies (24/39), 27% had anti-
double-strand DNA (dsDNA) antibodies (9/33) and 42% had 
antihistone antibodies (5/12) [Fig. 2]. Twenty-two percent 
(9/41) of patients demonstrated haematological abnormali-
ties, most frequently pancytopenia, lymphopenia, leukopenia 
or hypocomplementaemia. In 29% of cases, other laboratory 
or clinical findings were apparent (12/41) [electronic sup-
plementary Table S1].
3.4  Treatment Approach
Numerous treatment approaches to mAb-induced SCLE 
were recorded (n = 49) [Table 2]. Preventative measures of 
sun avoidance and ultraviolet (UV) protection were gener-
ally unambiguously applied; therefore, we focused on thera-
peutics pertinent to clinical decision making. Sixteen per-
cent of patients (8/49) were treated with biologic cessation 
alone as first-line. One of these patients started the DMARD 
hydroxychloroquine, however the rash had already started 
to improve [30]. Some patients did not initially stop their 
mAb therapy until the drug-induced nature of the rash was 
suggested; two of three patients did not see improvement 
until cessation of the drug despite starting topical corticos-
teroid creams at rash onset [31, 32]. For 38 of the remain-
ing patients, mAbs were stopped in combination with other 
therapies.
The most common medications applied were oral and/or 
topical corticosteroids. Thirty-one percent of patients were 
treated with topical corticosteroids alone (15/49), with tri-
amcinolone 0.1% ointment being the most frequently used 
topical corticosteroid. Thirty-seven percent of patients were 
treated with oral corticosteroids (18/49), either alone (n = 5) 
or in combination with disease-modifying antirheumatic 
drugs (DMARDs; n = 4), topical corticosteroids (n = 3), 
both these therapies (n = 5) or other immune-modulating 
therapies (n = 1). One patient received infliximab and 
oral prednisolone, but infliximab was discontinued after 
5 months due to a lack of response [33]. With sun protec-
tion and topical corticosteroids added, the skin eruptions of 
this patient resolved within 1 month [33]. Thirty percent of 
patients received DMARDs (15/49) alone or in combination. 
The DMARDS used first-line included hydrochloroquine 
Fig. 2  a Time course and b, c proportion of monoclonal antibody-
induced subacute cutaneous lupus cases demonstrating particular 
clinical features. Orange confidence intervals illustrated in b, c show 
the potential range of results if all missing data were a positive or 
negative result. ANA antinuclear antibody
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(n = 10), chloroquine (n = 2), mycophenolate (n = 2) and 
quinacrine (n = 1), making hydroxychloroquine the most 
used DMARD. A higher proportion of patients started on 
DMARD therapy had more clinical findings reported (53%, 
n = 8/15) than those not receiving DMARDs (15%, n = 4/26). 
Only one patient received a calcineurin inhibitor as part of 
therapy [34].
3.5  Prognosis
Eighty-nine percent of patients were reported to respond 
partially or fully to first-line therapy (30/45). One patient 
experienced a flare when corticosteroids were weaned, 
and again when hydroxychloroquine was introduced as a 
corticosteroid-sparing agent [35]. Ten patients went on to 
have second-line therapy or dose adjustments for their mAb-
induced SCLE due to non-response or partial response. Most 
commonly, a DMARD was added for patients receiving 
corticosteroid therapies; 9/10 of these patients responded 
to second-line therapy and recovered. Overall, where SCLE 
lesions responded to first-line therapy with complete or 
partial resolution, it took a median of 3.5 weeks (IQR 3–12, 
n = 26). Alongside sun protection, patients who were man-
aged by stopping mAb therapy alone saw improvement or 
resolution of skin lesions within a median of 3 weeks (IQR 
3–3.8, n = 6). Seventy-five percent of patients (9/12) receiv-
ing topical corticosteroids alone showed response to this 
therapy within 3 weeks. For all patients, it took a median of 
8 weeks for lesions to resolve (IQR 3–17, n = 33).
3.6  mAb Use
In 2013, the mAbs with the highest sales were adalimumab, 
infliximab, etanercept, rituximab and bevacizumab. By 
2018, the highest sales were attributed to adalimumab, 
etanercept, pembrolizumab, trastuzumab and bevacizumab. 
From modelling 2013–2018 global sales against estimated 
yearly therapy costs, the mAbs with the estimated highest 
yearly number of users were adalimumab, denosumab, ritux-
imab, etanercept and infliximab (Table 3).
With a high average therapy cost, pembrolizumab had 
68,000 estimated yearly users, compared with adalimumab 
Table 2  Summary of patient characteristics experiencing monoclonal antibody-induced subacute cutaneous lupus erythematosus
ANA antinuclear antibodies, PO per oral, TOP topical, DMARD disease-modifying antirheumatic drug, IQR interquartile range, SCLE subacute 
cutaneous lupus erythematosus, dsDNA double-stranded DNA
Trait Percentage Further detail Monoclonal antibody No. of SCLE cases
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with an estimated 615,000 yearly users. The number of 
SCLE cases attributable to checkpoint inhibitors such as 
pembrolizumab and nivolumab showed an especially high 
ratio of SCLE relative to the estimated yearly users (Fig. 3). 
Pembrolizumab and nivolumab target programmed cell-
death-1 (PD-1) antigens, while another checkpoint inhibitor 
ipilimumab targets cytotoxic T-lymphocyte-associated anti-
gen-4 (CTLA-4). In contrast, ipilumumab was not associated 
with any cases but showed reduced numbers of estimated 
yearly users compared with pembrolizumab and nivolumab. 
The anti-TNFɑ agents included (adalimumab, etanercept, 
infliximab, golimumab and certolizumab pegol) show an 
elevated rate of SCLE relative to the estimated yearly users, 
especially when compared with other highly used drugs such 
as denosumab and rituximab. The exception was certoli-
zumab pegol, which is a modified fragment of an mAb and 
is estimated to have many fewer annual users than other anti-
TNFɑ agents (Table 3). Ustekinumab targeting interleukin 
(IL)-23 and IL-12, and omalizumab targeting immunoglobu-
lin (Ig) E Fc regions were not associated with SCLE cases 
despite a high number of estimated users (approximately 
190,000 and 121,000, respectively).
4  Discussion
To the best of our knowledge, this systematic review is the 
first to explicitly define clinical criteria for SCLE to robustly 
determine the inclusion of patients. With increasing mAb use 
and rising rates of drug-induced SCLE (DI-SCLE) [14], we 
systematically reviewed for the first time the clinical course 
and treatment approach for mAb-induced SCLE. To derive 
the rates of SCLE relative to the estimated number of users of 
mAb, we modelled estimated yearly users from global sales 
and average treatment costs across a number of indications.
4.1  Inclusion Criteria
The devised scoring criteria combined multiple clinical fac-
tors to reflect the diagnostic approach to SCLE [18, 19, 36]. 
Table 3  Estimated monoclonal antibody use according to total global sales and average global cost
mAb monoclonal antibody, US$ United States dollars, GBP Great British pound, max maximum, min minimum
a 2013–2018 global sales were used to calculate the estimated monoclonal antibody yearly users. 2018 data are shown here
b Maximum value is based on electronic supplementary Table S2, while minimum value is based on electronic supplementary Table S3, with 1 
GBP converted to 1.524 US$
mAb Total global sales in 2018 
(US$, $m)a
Mean global mAb cost [US$ (min–
max)]b
Average estimated mAb yearly users across 
the years 2013–2018 [in thousands (min–
max)]
Adalimumab 19,952 34,870 (14,141–55,614) 615 (331–1524)
Etanercept 7611 30,105 (11,085–49,142) 276 (149–713)
Pembrolizumab 7171 107,625 (80,214–135,072) 68 (40–109)
Trastuzumab 7053 47,119 (19,869–74,389) 160 (90–367)
Bevacizumab 6919 86,810 (36,383–137,278) 84 (49–193)
Rituximab 6821 23,559 (6323–38,153) 305 (172–1102)
Aflibercept 6746 38,425 (9378–67,491) 187 (77–818)
Nivolumab 6735 102,425 (40,614–164,291) 70 (37–179)
Infliximab 6593 22,790 (15,730–29,854) 297 (209–440)
Ustekinumab 5156 28,586 (15,280–42,415) 190 (86–435)
Denosumab 4077 13,069 (3804–22,341) 325 (131–1286)
Ranibizumab 3722 32,341 (10,187–54,514) 125 (63–396)
Eculizumab 3563 547,771 (509,185–586,412) 7 (3–10)
Golimumab 2977 33,712 (15,244–52,192) 94 (51–216)
Omalizumab 2970 26,148 (12,696–39,619) 121 (61–277)
Abatacept 2710 28,158 (18,677–37,653) 99 (63–162)
Tocilizumab 2182 28,920 (15,782–42,081) 79 (34–187)
Natalizumab 1864 47,775 (22,463–73,110) 41 (23–89)
Cetuximab 1451 80,792 (15,351–146,256) 19 (9–103)
Certolizumab pegol 1446 34,460 (11,632–50,322) 45 (17–163)
Palivizumab 1381 22,914 (9139–36,697) 63 (34–167)
Iplimumab 1330 123,321 (114,373–132,282) 11 (8–14)
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In isolation, the specificity of many criteria is limited [12, 
37, 38]. Features delineating subacute and chronic forms 
of CLE include the presence of scarring/induration [37], 
duration of the rash, and the extent of histology findings. 
However, such features lack discriminatory boundaries for 
the spectrum of presentations [36, 37] and scarring does not 
present in the initial phases of the disease. Unlike typical 
adverse drug reactions, drug-induced cases of SCLE may 
present after an extended lag phase of drug exposure [14] 
and resolution of the condition may not necessarily follow 
drug cessation [39]. Some lesion types have been rarely 
considered as forms of SCLE, for example with gyrate, bul-
lous or nodular appearances [40, 41]. In keeping with the 
EUSCLE categories [18], these lesion types were considered 
to be non-specific LE forms and were not included in our 
morphological criteria of SCLE. We opted for a specific 
set of phenotypes to promote clear and comparable use of 
diagnostic terms, aiming to assist in research and clinical 
management.
4.2  Clinical Associations
Previous reviews on the patient demographics of DI-SCLE 
and non-DI-SCLE cases found comparable characteristics 
as those identified in this review [42–45]. Similar to other 
patients with DI-SCLE, mAb-induced SCLE most com-
monly occurred in White female patients with a mean age of 
diagnosis between 40 and 65 years [14, 42], suggesting com-
mon susceptibility factors or simply reflecting the majority 
demographic of patients being administered these medica-
tions. The time course of mAb-induced SCLE was similar to 
a series of DI-SCLE where a median of 3–8 weeks to onset 
and 4–9 weeks to resolution was reported [43, 45].
For the variables considered, we did not find compelling 
evidence to suggest a distinct difference between the mAb-
induced SCLE phenotype and DI-SCLE more generally. 
Compared with recent DI-SCLE studies [14, 43, 45, 46], 
this systematic review found a similar proportion of patients 
with detectable anti-Ro antibodies (62% in this review vs. 
72.1–100%), ANA (85% in this review vs. 64–100%) and 
anti-dsDNA antibodies (27% vs. 21%) [45]. Anti-Ro anti-
bodies are associated with drug-induced SLE in a minority 
of patients (< 5% [47]), however, consistent with the litera-
ture, we found a much higher proportion of seropositive 
patients in SCLE. A previous literature review reported a 
higher prevalence of anti-dsDNA antibodies in mAb-induced 
SCLE compared with DI-SCLE—91% vs. 1% [48], a find-
ing not supported by our review. Compared with the series 
of 88 patients with DI-SCLE by Laurinaviciene et al. [45], 
the difference in anti-Ro and anti-dsDNA antibody status 
was not significant within the sample size (p = 0.2678 and 
p = 0.5988, respectively).
Patients with systemic features in association with mAb-
induced SCLE exhibited a similarly mild course to that 
reported in DI-SCLE [19], with no cases of lupus nephritis 
or CNS involvement [42]. Lesions over the legs have been 
depicted as being more typical of DI-SCLE than idiopathic 
SCLE [43], which was supported by our finding of 30% of 
patients with leg involvement. The distribution alone sug-
gests that photosensitivity may play less of a role in the 
pathophysiology of mAb-SCLE compared with classical 
SCLE. No cases with an explicit clinical SCLE diagnosis 
Fig. 3  Ratio of total cases 
(monoclonal antibody-induced 
SCLE) against the annual 
estimated monoclonal antibody 
users as a percentage. Therapies 
utilising anti-tumour necrosis 
factor-ɑ mechanisms are high-
lighted in yellow and anti-PD-1 
drugs are shown in orange. 
SCLE subacute cutaneous lupus 
erythematosus, PD-1 pro-
grammed cell death-1
327Systematic Review: Monoclonal Antibody-Induced Subacute Cutaneous Lupus Erythematosus
described lesions over the feet or the hands alone. In con-
trast, two patient cases that were excluded for non-specific 
lesion morphology showed lesions on the fingers and toes, 
with a dose onset that diverged from the IQR described [49, 
50]. This suggests that lesions on the fingers or toes, in isola-
tion, should prompt reconsideration of the diagnosis.
4.3  Treatment
Treatment modalities for CLE lack expert consensus or 
licencing [51], with extreme variation seen in surveys of 
dermatologists from Japan, Europe and the US [11]. Our 
analysis of the 49 patient cases with documented treatment 
confirmed this lack of standardised approach with a wide 
variety of treatment strategies used. There is a paucity of 
high-quality evidence for SCLE treatment [51]. At the time 
of writing, there were no active trials registered exclusively 
for SCLE on ClinicalTrials.gov [52] (last searched 6 April 
2020). However, phase II trials are underway for janus 
kinase 1 (JAK1) inhibitors in CLE, and registries are being 
established to advance understanding.
Topical corticosteroids are considered to be the mainstay 
for limited cutaneous disease in CLE [11, 20, 51]. Topical 
calcineurin inhibitors have been suggested for corticoster-
oid-refractory SCLE [20]; however, a previous systematic 
review found such therapy to be less efficacious in SCLE 
compared with other CLE subtypes [53]. In terms of sys-
temic options, DMARDs, specifically antimalarials, have 
long been used for their immunomodulating effects and 
avoidance of corticosteroid adverse effects [11]. The evi-
dence base for this therapy in SCLE derives largely from 
one randomised blinded study of 12 patients in 1992 [51, 
54], as well as clinical experience. Among the 19 patients 
who recovered fastest in our review (within 3 weeks), topical 
corticosteroids were most frequently used (n = 9); however, 
this rapid resolution likely reflects a milder disease presen-
tation influencing clinicians in their management approach, 
as many other patients receiving topical corticosteroids and 
systemic agents showed a more prolonged course. Oral cor-
ticosteroids were widely used; however, recommendations 
suggest their use should be limited to severe disease [51] 
because of the frequency of adverse effects.
4.4  mAb Use
Given the rarity of SCLE, if there is a specific genetic, 
epigenetic, or pharmacokinetic context that predisposes a 
patient to mAb-induced SCLE, then greater use of a drug 
will heighten the likelihood of a predisposed patient receiv-
ing the triggering drug. However, we wanted to determine 
if the difference in case numbers reported for different 
mAbs simply reflected the differing number of yearly users. 
Following modelling of yearly users, we identified that anti-
TNFɑ agents and checkpoint inhibitors were associated with 
a propensity for mAb-SCLE relative to their use. Given the 
recent licencing of nivolumab and pembrolizumab, their 
high relative rates of SCLE are particularly stark.
Immune checkpoint inhibitors blocking PD-1 or CTLA-4 
pathways are utilised to reduce immune tolerance of malig-
nancy and T-cell anergy [55]; however, a loss of the inhibi-
tory signals transmitted by such pathways may tip the bal-
ance towards T-cell-mediated inflammation and destruction 
of self-tissues [55]. Such an association between check-
point inhibitors, CLE and other autoimmune dermatoses 
is increasingly being recognised. Further support for an 
association is illustrated by the lupus-like graft-versus-host 
syndrome in 2C-TCR-transgenic PD-1-deficient H-2b/d mice, 
where skin lesions with dense inflammatory cell infiltrate 
in the dermis and liquefaction degeneration were observed 
[56]. The difference in SCLE cases associated with mAbs 
acting on PD-1 compared with CTLA-4 may be related to 
their primary site of action, with CTLA-4 limiting early 
T-cell responses, particularly in lymphoid tissues, and PD-1 
limiting T-cell responses later in peripheral tissues [57]. 
While the propensity to immune-mediated adverse effects 
in patients taking checkpoint inhibitors is intuitive, further 
work is needed to understand why SCLE is induced in only 
a tiny proportion of patients receiving these therapies.
We considered whether the relatively high rate of SCLE 
associated with anti-TNFɑ agents could reflect a publica-
tion bias, with rheumatologists more likely to diagnose and 
publish cases attributable to drugs they frequently use. How-
ever, we found more cases were reported by dermatologists 
than rheumatologists, and such a trend was not consistent 
across other rheumatological therapies of rituximab, usteki-
numab or tocilizumab (Fig. 3). Multiple previous studies 
have reported an association between anti-TNFɑ agents and 
the induction of CLE [47, 58]. TNFɑ is a cytokine involved 
in myriad signalling pathways of apoptosis, inflammation 
and immune regulation depending on the cellular context 
[59–61]. This wide array of cellular effects in different cell 
types may account for the conflicting findings of both the 
beneficial and antagonistic effects of TNFɑ on lupus in ani-
mal models [62, 63] and a small number of case reports [42, 
64]. The significance of specific TNF pathways, and even 
anti-TNF mechanisms, are not well understood in CLE [65]. 
mAbs targeting TNFɑ do not only bind and sequester solu-
ble cytokine but may also induce apoptosis [66–68], inhibit 
reverse signals from transmembrane TNFɑ [69] or enhance 
regulatory T-cell interactions [70]. Nonetheless in larger-
scale studies, the − 308A TNFɑ promoter polymorphism 
has been associated with an increased risk of SCLE [71], 
and cutaneous TNF genes are significantly differentially 
expressed in CLE compared with controls [20].
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4.5  Limitations
A multispecialty panel devised our inclusion criteria for 
the purpose of this review, therefore external validation is 
required. As most papers we included reported retrospective 
case series, this review was limited by incomplete data from 
reported cases. Some tests were not performed, however this 
is reflective of routine clinical care. Eight of the included 
sources came from conference abstracts, suggesting that grey 
literature was incorporated in the review; however, further 
hand searching would reduce publication bias further. The 
methodology has a language bias, with search strategies per-
formed in the English language; we were unable to include 
non-European language papers in the screening process.
Annual mAb use was intended to provide a relative esti-
mate of global use, however due to limited available pre-
scription data of this kind, it is difficult to validate against 
existing data. The approximate annual costs utilised averages 
across two countries and cannot fully reflect the broad array 
of regimens used by physicians. Some mAb therapies have 
been licenced for many more years than others; for exam-
ple, rituximab was licenced in 1997. Therefore, using esti-
mated patient users across 1 year underestimates exposure 
of patients to the older drugs, as it does not incorporate the 
decades of use. Given this, the relationship between check-
point inhibitors and mAb-induced SCLE is more striking as 
they have been licenced in the last decade.
5  Conclusion
Within the disease subtype of mAb-induced SCLE, there 
is great variability in serological findings, lesion distribu-
tion, treatment approach, and even the range of synonyms 
used for diagnostic terms. As the sheer complexity of the 
mechanisms governing tolerance and autoimmunity are fur-
ther uncovered, clear phenotypic distinction and clarity of 
terms are vital to furthering understanding. To this end, we 
present the first systematic review of mAb-induced SCLE.
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